Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Carcinoma, Ovarian Epithelial 3

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 329Cisplatin 276Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 210Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Has results × CCV-AV protocol × Clear all
NCT01617629 2017-12-08

CAN-003X

Prima BioMed Ltd

Phase 2 Completed
9 enrolled 7 charts
Gynecologic

Carcinoma, Ovarian Epithelial

NCT01068509 2017-05-11

Ovarian Cancer Vaccine for Patients in Remission

Prima BioMed Ltd

Phase 2 Completed
63 enrolled 9 charts
Gynecologic

Carcinoma, Ovarian Epithelial

NCT01521143 2016-12-14

CANVAS

Prima BioMed Ltd

Phase 2 Terminated
91 enrolled 5 charts
Gynecologic

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡